Published Nov 20, 2014
Fort Worth, TX, USA - Venous leg ulcers (VLUs) affect up to 2.5 million people per year in the USA at an estimated cost of 14.9 billion dollars annually.  The longer it takes to heal a VLU, the greater the financial burden to the health care system. Cellular/tissue-derived products (CTPs) are often used in conjunction with compression therapy to treat refractory cases of VLU, however, little is known regarding the cost-effectiveness of the most commonly used CTPs. Researchers from Strategic Solutions Inc. conducted a cost-effectiveness analysis of three frequently used CTP VLU therapies using economic and clinical outcome information available in the medical literature.  The study determined that a porcine derived extracellular matrix (ECM) was a cost saving therapeutic option when compared to human skin equivalent (HSE) and living skin equivalent (LSE). The expected wound closure rates were 75% for ECM, 70% for LSE and 69% for HSE. The cost per episode of VLU care was estimated at $6,732 for ECM compared to $10,638 for HSE and $11,237 for LSE. “The higher wound closure rate shown by the ECM product provided substantial clinical benefit for patients with an economic benefit for payers. The longer a wound remains unhealed the greater the additional costs,” said lead researcher, Dr. Marissa J. Carter, PhD. “Closing the wound earlier with an ECM improves patient outcomes, reduces health care resource utilization and lowers the overall costs of VLU care.” The full study, “Cost-Effectiveness of Three Adjunct Cellular/Tissue-Derived Products Used in the Management of Chronic Venous Leg Ulcers,” is published in Value in Health.

Related Stories

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.

ISPOR Good Practices Report Offers Guidance for Using Real-World Data From EHRs in Health Technology Assessments

Jun 17, 2024

ISPOR announced the publication of an ISPOR Good Practices Report that proposes a framework for assessing the suitability of electronic health records data for use in health technology assessments. The report, “Assessing Real-World Data from Electronic Health Records for Health Technology Assessment: The SUITABILITY Checklist: A Good Practices Report of an ISPOR Task Force” was published in the June 2024 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now